Levodopa responsiveness in disorders with parkinsonism: A review of the literature

Movement Disorders

Volumn 22, Issue 15, 2007, Pages 2141-2148

  Constantinescu, Radu ^a   Richard, Irene ^a   Kurlan, Roger ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Mt Hope Professional Building ^*  (United States)

Author keywords

Levodopa; Levodopa response; Parkinson's disease; Parkinsonian disorders; Parkinsonism

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; PLACEBO;

CORTICOBASAL DEGENERATION; DEMENTIA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; INVOLUNTARY MOVEMENT; LEWY BODY; MENTAL DISEASE; MOTOR DYSFUNCTION; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SIDE EFFECT; SPINOCEREBELLAR DEGENERATION; TARDIVE DYSKINESIA; TREATMENT RESPONSE;

ANTIPARKINSON AGENTS; EDUCATION, MEDICAL, CONTINUING; HUMANS; LEVODOPA; PARKINSONIAN DISORDERS;

EID: 38049019848     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21578     Document Type: Review

References (76)

1. Suchowersky O, Reich S, Perlmutter J, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968-975.
2. Litvan I, Bhatia KA, Burn DJ, et al. Movement Disorder Society Scientific Issues Committee Report. SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
3. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
4. Hughes AJ, Lees AJ, Stern GM. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurology 1991;41:1723-1725.
5. Yahr MD, Duvoisin RC, Schear MJ, et al. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-354.
6. Tolosa ES, Martin WE, Cohen HP, et al. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology 1975;25:177-183.
7. Lees AJ, Stern GM. Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up. Adv Neurol 1983;37:9-15.
8. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50: 140-148.
9. Wenning GK, Ben-Shlomo Y, Hughes AJ, et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;68:434-440.
10. Mark MH, Sage JI, Dickson D, W., et al. Levodopa-nonresponsive Lewy body parkinsonism: clinicopathologic study of two cases. Neurology 1992;42:1323-1327.
11. Bonnet A-M. Involvement of non-dopaminergic pathways in Parkinson's disease: pathophysiology and therapeutic implications. CNS Drugs 2000;13:351-364.
12. Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. Arch Neurol 2006;63:354-357.
13. Ghaemi M, Raethjen J, Hilker R, et al. Monosymptomatic resting tremor and Parkinson's disease: a multiracer positron emission tomographic study. Mov Disord 2002;17:782-788.
14. Colosimo C, Tiple D, Wenning GK. Management of multiple system atrophy: state of the art. J Neural Transm 2005;112:1695-1704.
15. Albanese A, Colosimo C, Bentivoglio AR, et al. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosci Neurosurg 1995;59:144-151.
16. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
17. Gilman S, May SJ, Shults CW, et al. The North American Multiple System Atrophy Study Group. J Neural Transm 2005;112:1687-1694.
18. Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord 2005;20:S67-S76.
19. Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2005;20:S83-S91.
20. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993;16:338-346.
21. Litvan I, Mangone CA, D'Olhaberriague L, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosci Neurosurg 1996;60:615-620.
22. Collins SJ, Shlskog JE, Parisi JE, et al. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosci Neurosurg 1995;58:167-173.
23. Williams DR, deSilva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-1258.
24. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
25. Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55:1099-1102.
26. Kumar R, Bergeron C, Pollanen MS, et al. Cortical basal ganglionic degeneration. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams and Wilkins;1998. p 297-316.
27. Lang AE, Riley DE, Bergeron C. Cortico-basal ganglionic degeneration. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: W.B. Saunders; 1994. p 877-894.
28. Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord 2001;16:252-257.
29. Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998;64: 184-189.
30. Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55:957-961.
31. Frucht S, Fahn S, Chin S, et al. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord 2000;15:340-343.
32. Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord 2003;18:884-889.
33. Molloy S, McKeith IG, O'Brien JT, et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005;76:1200-1203.
34. Bonelli SB, Ransmayr G, Steffelbauer M, et al. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004;63:376-378.
35. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449-1468.
36. Joyce JN, Ryoo HI, Beach TB, et al. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res 2002;95:138-152.
37. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord 2005;20:S77-S82.
38. Papapetropoulos S, Lieberman A, Gonzalez J, et al. Family history of dementia: dementia with Lewy bodies and dementia in Parkinson's disease. Neuropsychiatry Clin Neurosci 2006;18:113-116.
39. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40: 767-775.
40. Papapetropoulos S, Paschalis C, Athanassiadou A, et al. Clinical phenotype in patients with α-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:662-665.
41. Saito M, Maruyama M, Ikeuchi K, et al. Autosomal recessive juvenile parkinsonism. Brain Dev 2000;22:S115-117.
42. Munhoz RP, Sa DS, Rogaeva E, et al. Clinical findings in a large family with a parkin ex3640 mutation. Arch Neurol 2004;61:701-704.
43. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005;58:411-422.
44. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. Susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-265.
45. Farrer M, Gwinn-Hardy K, Muenter M, et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet 1999;8:81-85.
46. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann Neurol 2004;55:174-179.
47. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-452.
48. Rogaeva E, Johnson J, Lang AE, et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004;61:1898-1904.
49. Albanese A, Valente EM, Romito LM, et al. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 2005;64:1958-1960.
50. Bonifati V, Breedveld GJ, Squitieri F, et al. Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol 2002;51:253-256.
51. Dekker M, Bonifati V, van Swieten J, et al. Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov Disord 2003; 18:751-757.
52. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005;128:2786-2796.
53. Di Fonzo A, Rohe CF, Ferreira J, et al. Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005;365:412-415.
54. Goldwurm S, Di Fonzo A, Simons EJ, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 2005;42:e65.
55. Williams DR, Hadeed A, Al-Din AS, et al. Kufor Rakeb Disease: Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005;20:1264-1271.
56. Pankratz N, Nichols WC, Uniacke SK, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 2002;71:124-135.
57. Pankratz N, Nichols WC, Uniacke SK, et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet 2003;72:1053-1057.
58. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002;52: 549-555.
59. Marx FP, Holzmann C, Strauss KM, et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 2003;12: 1223-1231.
60. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102.
61. Demirkiran M, Bozdemir H, Sarica YV. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand 2001; 104:63-67.
62. Rampello L, Alvano A, Battaglia G, et al. Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism. J Neurol 2005;252:1045-1049.
63. Zijlmans JC, Katzenschlager R, Daniel SE, et al. The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 2004;75:545-547.
64. FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord 1989;4:249-260.
65. Schols L, Peters S, Szymanski S, et al. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 2000;57:1495-1500.
66. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family. Arch Neurol 2001;58:296-299.
67. Wilder-Smith E, Tan EK, Law HY, et al. Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. J Neurol Sci 2003;213:25-28.
68. Nandagopal R, Moorthy SG. Dramatic levodopa responsiveness of dystonia in a sporadic case of spinocerebellar ataxia type 3. Post-grad Med J 2004;80:363-365.
69. Wu YR, Lin HY, Chen CM, et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. Clin Genet 2004;65:209-214.
70. Stephen PJ, Williamson J: Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-1083.
71. Melamed E, Achiron A, Shapira A, et al. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 1991;14: 273-278.
72. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology 1993;43:552-556.
73. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18:S28-S33.
74. Lee PH, Kim JS, Shin DH, et al. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2006;77:372-374.
75. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850-854.
76. Chouinard G, Annable L, Mercier P, et al. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 1987;23:221-226.